OGIVRI is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Mylan Institutional Llc. The primary component is Trastuzumab.
Product ID | 67457-991_07ab2fd4-cfe5-4cff-81bf-499602e5999c |
NDC | 67457-991 |
Product Type | Human Prescription Drug |
Proprietary Name | OGIVRI |
Generic Name | Trastuzumab |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2019-11-29 |
Marketing Category | BLA / BLA |
Application Number | BLA761074 |
Labeler Name | Mylan Institutional LLC |
Substance Name | TRASTUZUMAB |
Active Ingredient Strength | 150 mg/7.4mL |
Pharm Classes | HER2/neu Receptor Antagonist [EPC],HER2/Neu/cerbB2 Antagonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2019-11-29 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761074 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2019-11-29 |
NDC | Brand Name | Generic Name |
---|---|---|
67457-845 | OGIVRI | trastuzumab |
67457-847 | OGIVRI | trastuzumab |
67457-991 | OGIVRI | trastuzumab |
50242-132 | Herceptin | Trastuzumab |
50242-134 | Herceptin | Trastuzumab |
50242-333 | Herceptin | Trastuzumab |
63459-303 | HERZUMA | TRASTUZUMAB |
63459-305 | HERZUMA | TRASTUZUMAB |
0006-5033 | Ontruzant | trastuzumab |
0069-0305 | Trazimera-qyyp | trastuzumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
OGIVRI 88650753 not registered Live/Pending |
Mylan Institutional Inc. 2019-10-11 |
OGIVRI 86970805 not registered Live/Pending |
Mylan Institutional Inc. 2016-04-11 |